AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have been assigned an average rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is £153.33.

A number of brokerages have recently weighed in on AZN. Shore Capital Group restated a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research note on Wednesday, May 6th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Citigroup boosted their target price on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research note on Friday, April 10th. Finally, Jefferies Financial Group restated a “buy” rating and issued a £180 target price on shares of AstraZeneca in a research note on Wednesday.

AstraZeneca Price Performance

Shares of LON AZN opened at £138.06 on Thursday. AstraZeneca has a twelve month low of GBX 9,932 and a twelve month high of £157.32. The stock’s 50 day moving average price is £144.18 and its 200-day moving average price is £140.37. The company has a market capitalization of £214.11 billion, a PE ratio of 20.79, a PEG ratio of 0.86 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.